TELA Bio, Inc. (TELA)

US — Healthcare Sector
Peers: MDAI  ICCM  CUE  NRXP  CTSO  SRTS  COEP  OTLK  SPRB  EQ 

Automate Your Wheel Strategy on TELA

With Tiblio's Option Bot, you can configure your own wheel strategy including TELA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TELA
  • Rev/Share 1.6964
  • Book/Share 0.2022
  • PB 5.5887
  • Debt/Equity 4.5625
  • CurrentRatio 3.1869
  • ROIC -0.6767

 

  • MktCap 45557245.0
  • FreeCF/Share -0.7634
  • PFCF -1.3138
  • PE -1.3161
  • Debt/Assets 0.6204
  • DivYield 0
  • ROE -3.1518

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade TELA Piper Sandler Overweight Neutral $5 $2 March 21, 2025

News

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a grant date of November 10, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception …

Read More
image for news TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings
TELA
Published: November 14, 2025 by: Benzinga
Sentiment: Negative

TELA Bio Inc (NASDAQ: TELA) reported mixed results for the third quarter on Thursday.

Read More
image for news These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings
TELA Bio Appoints Jeffrey Blizard as President
TELA
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth

Read More
image for news TELA Bio Appoints Jeffrey Blizard as President

About TELA Bio, Inc. (TELA)

  • IPO Date 2019-11-08
  • Website https://www.telabio.com
  • Industry Medical - Devices
  • CEO Antony Koblish
  • Employees 209
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.